Nonprofit group helps doctors and startups bring new cardiovascular tech to market
Nabil Dib, MD, founder of the nonprofit International Society for Cardiovascular Translational Research (ISCTR), spoke to Cardiovascular Business about the different resources ISCTR has developed to help doctors navigate the shift from conducting research to developing clinical applications.
"If you want to develop a drug or a device, it will take on average 20 years and take between $1.6 billion and $2 billion. What we put together are courses and eBooks on innovation that standardize medical product development, from identifying a patient need, developing intellectual property, understanding engineering language so you can communicate effectively, choosing the right animal models, understanding the clinical research and how to design trials with an important clinical endpoint. And all these things will meet the requirements for regulatory pathways," Dib, who is also the director of clinical and translational research with Dignity Health, explained.
The mission of ISCTR is to help move things more rapidly for new technology development by sharing the knowledge of those with previous experience. It provides a collaboration and guidance among academia, industry, regulatory agencies, reimbursement agencies, practice guidelines and patients to expedite scientific discoveries into commercialized products.
Dib is president of the organization, and its board of directors includes top innovators in cardiology such as Anthony DeMaria, Mitchell W. Krucoff, Spencer B. King, Martin B. Leon, Ron Waksman, Bram Zuckerman, Antonio Colombo, Jeroen Bax, David R. Holmes, Kenneth Stein, Chuck Simonton, Daniel Burkhoff, Todd J. Brinton, and others.